Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683239 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,331
- Enrollment target
NCT02683239: Completed Phase 3 study, sponsored by Regeneron Pharmaceuticals.
NCT02683239 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 5,331 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (591% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02683239, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,331 participants
- Enrollment target
Study Summary
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
Interventions
- DRUG Placebo
- DRUG Fasinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,331 participants |
| Start Date | 2016-02-17 |
| Est. Completion | 2021-06-15 |
| Phase | Phase 3 |
What the finished NCT02683239 record still lists
NCT02683239 is an interventional study that assigns participants to a tested intervention. Its 5,331 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (591% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02683239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02683239 about?
NCT02683239 is a clinical study titled "Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip". The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
What is the current status of trial NCT02683239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,331 participants. The study started on 2016-02-17. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT02683239?
The interventions under investigation include: Placebo (DRUG), Fasinumab (DRUG).
Who is sponsoring clinical trial NCT02683239?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02683239's enrollment target sits among peer trials
5,331 46th of 2000 higher than 1,955 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI